MIP-5 activators encompass a set of chemical compounds that specifically target or indirectly modulate the expression or activity of the MIP-5 chemokine. The core principle guiding the impact of these activators is the common cellular pathway of NF-κB activation. As a pivotal transcription factor, NF-κB plays a central role in immune responses, inflammation, and more critically, in the transcriptional regulation of chemokines, including MIP-5. When activated by various stimulants, NF-κB migrates to the nucleus and binds to specific DNA sequences, particularly in the promoter regions of target genes. In the context of MIP-5, NF-κB binding to its promoter enhances its transcription, thereby elevating its levels.
MIP-5 activators, as outlined here, primarily function by engaging different Toll-like receptors (TLRs), a family of pattern recognition receptors (PRRs) that detect microbial components and instigate innate immune responses. Each TLR has its unique ligand specificity, from bacterial cell wall components like LPS and LTA (targeting TLR4 and TLR2 respectively) to viral mimetics like Poly(I:C) (targeting TLR3). Activation of these receptors invariably converges on a common downstream effect: NF-κB pathway stimulation. The variety of these activators underscores the redundancy and interconnectedness of the body's defense mechanisms. Additionally, some compounds like PMA bypass TLRs but still stimulate the NF-κB pathway by targeting protein kinases. Such an integrated system ensures that any perturbation, be it microbial invasion or cellular stress, is aptly met with an appropriate chemokine response, signified in this context by MIP-5 production.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $96.00 $166.00 $459.00 $1615.00 | 12 | |
LPS stimulates the Toll-like receptor 4 (TLR4) pathway, which leads to the activation of NF-κB. This, in turn, upregulates the transcription of various chemokines, including MIP-5. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates the PKC pathway, which can stimulate the NF-κB pathway. As NF-κB can bind to the promoter region of MIP-5, PMA indirectly leads to enhanced transcription of MIP-5. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $650.00 | 2 | |
Poly(I:C) mimics double-stranded RNA, activating TLR3. This leads to downstream activation of NF-κB, which can enhance the transcription of MIP-5. | ||||||
Lipoteichoic acid | 56411-57-5 | sc-507479 | 5 mg | $248.00 | ||
LTA stimulates the TLR2 pathway, leading to NF-κB activation. NF-κB subsequently binds to the promoter region of various chemokines, including MIP-5, leading to its increased transcription. | ||||||
Zymosan | 9010-72-4 | sc-296863 sc-296863A | 100 mg 1 g | $97.00 $587.00 | 1 | |
Zymosan activates the TLR2/6 pathway. Activation of this pathway can lead to the upregulation of NF-κB which, in turn, promotes MIP-5 transcription. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
Imiquimod is a TLR7 agonist. Its activation results in NF-κB stimulation, which can bind to the promoter region of MIP-5, promoting its transcription. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $154.00 $276.00 $506.00 $1154.00 $19743.00 $32136.00 $69366.00 | 1 | |
Gardiquimod activates TLR7, leading to the activation of NF-κB. NF-κB can bind to the promoter region of MIP-5, increasing its transcription. | ||||||
CL097 | 1026249-18-2 | sc-507394 | 5 mg | $135.00 | ||
CL097 is a TLR7/8 agonist. It stimulates the NF-κB pathway, which can enhance the transcription of MIP-5 by binding to its promoter region. | ||||||